4D Molecular Therapeutics, Inc. FDMT 深 沪
已收盘 04-02 16:00:00 美东时间
9.48
-0.390
-3.95%
华盛通- 最 高9.83
- 今 开9.50
- 成交量 70.69万股
- 最 低 9.375
- 昨 收 9.87
- 总市值 4.84亿
- 52周最高 12.34
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 2.56
- 委 比 -73.92%
- 总股本 5105.15万
- 历史最高 55.11
- 量 比 0.60
- 振 幅 4.61%
- 历史最低 2.235
- 每 手 1
- 风险率 2.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan March 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ferguson Enterprises, Hartford Insurance Group and JP Morgan, on Monday. HIGHLIGHT
03-30 15:35
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.
03-19 22:04
UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.53) by 181.13 percent. This is a 147.78 percent increase over losses of $(0.90) per
03-19 04:34
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported positive progress in 2025, including rapid enrollment completion in the 4FRONT-1 Phase 3 trial for wet AMD, strategic partnership with Otsuka with $85 million upfront payment, and $118 million financing. The company expects topline data for wet AMD in H1 2027 and initiation of the global Phase 3 trial for DME in Q3 2026. Cash reserves of $514 million are sufficient to fund operations into H2 2028.
03-18 20:05
4DMT to Participate in Upcoming Investor Meetings
<p>4D Molecular Therapeutics (4DMT) announced that its management will present and participate in investor meetings at the <em>Leerink Partners Mountain Meeting</em> (March 22-25, 2026) and the <em>RBC Capital Markets Global Ophthalmology Conference</em> (March 24, 2026, at 3:45 p.m. GMT). The company is focused on developing durable and disease-targeted therapeutics, with its lead product candidate 4D-150 in Phase 3 for wet age-related macular d...
03-16 12:00
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (4DMT) announced that its management will present at three upcoming investor conferences in March. The company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. ET; the Leerink Global Healthcare Conference on March 10, 2026, at 4:20 p.m. ET; and the Barclays 28th Annual Global Healthcare Conference on March 12, 2026, at 9:00 a.m. ET. Webcast links are available on the com...
02-19 13:00
4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide
02-09 21:12
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4DMT announced the completion of enrollment for its Phase 3 trial 4FRONT-1 evaluating 4D-150 for wet AMD. The trial enrolled over 500 patients ahead of schedule within 11 months, reflecting strong interest. Topline results are expected in H1 2027. Enrollment for the global Phase 3 trial 4FRONT-2 is on track to complete in H2 2026, with data expected in H2 2027. 4D-150 aims to reduce treatment burden with a single injection providing durable anti-...
02-09 13:00
